Trial intelligence / Profile preview

Phase 2b study of presatovir (GS-5806) in hospitalized adults with RSV infection

2014-002137-58Phase 2Completed

Sponsor
Gilead Sciences
Start
Sep 2014
Modality
Small Molecules
Countries
1
01

Overview

Phase 2, randomised, double-blind trial in respiratory syncytial virus disease (RSV) comparing Presatovir arm with Placebo arm (2 arms). Primary endpoint: Time-weighted average change in log10 viral load from baseline to Day 5. Started Sep 2014; status: completed.

02

Drugs

presatovir
03

Conditions

respiratory syncytial virus disease (RSV)

Beyond the preview

Go deeper on 2014-002137-58.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2014-002137-58.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call